← Eichor
Study identifier: NCT07260669 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Condition: Endometriosis  ·  Sponsor: Gesynta Pharma AB

PhasePhase 2
Planned participants190
Who can joinFemale, 18 Years to 44 Years
Healthy volunteersNo

About this study

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

This description comes directly from the study's public registry record.

Talk to the study team

CMO VP Clinical Development  ·  +46 762 788 389  ·  ctg@gesynta.se

Always discuss trial participation with your own doctor first.

Locations (41)

MHAT Puls ADBlagoevgrad, BulgariaRecruiting
Lyulin HospitalSofia, BulgariaRecruiting
FemiClinicSofia, BulgariaRecruiting
Gynekologie MEDA s.r.oBrno, CzechiaRecruiting
Fakultni nemocnice BrnoBrno, CzechiaRecruiting
NEUMED Gynekologicka Ambulance s.r.o.Olomouc, CzechiaRecruiting
Gyncare MUDr. Michael Svec s.r.o.Pilsen, CzechiaRecruiting
STELLA-GYN, s.r.o.Vodňany, CzechiaRecruiting
MedEndBudapest, HungaryRecruiting
Semmelweis Egyetem II. Sz. Szuleszeti es Nogyogyaszati KlinikaBudapest, HungaryRecruiting
Robert Karoly Private Hospital Tritonlife Medical CenterBudapest, HungaryRecruiting
Debreceni Egyetem Klinikai KozpontDebrecen, HungaryRecruiting

+ 29 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07260669